MEDICAL CANNABIS FOR THE PEOPLE
We are Raphael Pharmaceutical, we are investing in the research and development of medicinal cannabis.
our goals
Market Goals
Start up in California, Oklahoma and Colorado, followed by expansion throughout the United States, Canada, Europe and the rest of the world.
Scientific Goals
To research and develop cannabis-based medical indication formulas for phase 2 approval by the United States Food and Drug Administration (FDA) and for clearance by the European Medicines Agency (EMA).
Business Goals
To outsource the manufacturing and distribution of our cannabis based medical indication formulas with GMP-approved medical cannabis manufacturers and licensed, approved cannabis distributors globally through royalty agreements that articulate Raphael Pharmaceutical will benefit from each and every sale.
treatments
Rheumatology diseases, arthritic joint inflammation, and chronic pain
Rheumatoid arthritis (RA)
Highly Purified Cannabinoid (HPC1) as a Treatment Option for Patients with Rheumatoid Arthritis (RA)
The Company has successfully completed the proof-of-concept phase in mice and signed an agreement with California-based Citruslabs to conduct a clinical trial in RA patients in the US. The clinical trial started at the beginning of May 2024 and is ongoing.
.png)
Autoimmune Disease
Restrain the inflammation storm in chronic lung inflammation
Oncology Patients
Personalized therapies
Cancer treatment effects like cachexia, fatigue, anemia, pain and depression
Researching cannabinoid's receptors to provide personalized therapies
Research Partners
Schneider Children's Medical Center of Israel
We have partnered with Schneider Children Hospital
to design a novel, cannabis-based treatment to relieve symptoms in young patients in the case of palliative effects of cancer treatment including cachexia, fatigue, anemia, pain, and depression.
Rambam Health Care Campus
We have partnered with Rambam's Medical Cannabis Research Team to develop cannabis-based
medical indications FDA approved.
Investors
Raphael Pharmaceutical – Company Overview
We are a pharmaceutical drug research and development company
focused on the discovery and clinical development of life-improving drug
therapies based on cannabinoids. We collaborate with world-class
research experts to harness the power of rigorous scientific methods
and advanced technologies to develop safe, effective cannabinoidbased
formulas. Our most advanced development candidates include
novel, patentable formulations designed to treat rheumatoid arthritis
(lead candidate), chronic lung inflammation and autoimmune disease.
Why Invest?
• Aligned Management Team and Prominent Scientific Advisory Board
• Exclusive Research Agreement with Rambam Health Care Campus
• Differentiated Cannabinoid Technology Platform
• Promising Lead Product Candidate for Rheumatoid Arthritis
• Near-Term Catalysts for Lead Product Candidate
• Large and Growing Rheumatoid Arthritis Market Opportunity
• Robust Pipeline Based on Platform Technology
Latest Press Releases:
July 9, 2024 – Raphael Pharmaceutical Issues Letter to Shareholders - PDF
Latest Investor Presentation
June 2024
Investor Relations Contact
Media & Publications
October 17, 2024
"Pharmaceuticals"
February 12, 2021
"Frontiers in immunology"
what makes us different
To achieve FDA Phase 2 approval, we are deciphering the mechanism by which cannabis is working. Far from anecdotal evidence, our research is conducted on the molecular and bio-chemical levels. Up to this point, studies of cannabis have been based on statistics. Raphael Pharmaceutical is going deeper by mapping the cannabinoid receptors and scientifically proving the therapeutic effects of cannabinoids on a variety of diseases.
our mission
The mission of Raphael Pharmaceutical is to recognize the therapeutic benefits of medical cannabis. We believe in producing the highest quality product, which is why we have invested in over six years of research with Israel's most renowned scientific institutions. Raphael Pharmaceutical cares for each individual and we believe that medical solutions should be accessible to everyone. Therefore, we intend to keep our products at an affordable cost for the well being of all.
our vision
innovators of the future
Raphael Pharmaceutical is building the prototype for its business model, having established approximately 30 vendor partnerships in California, including with a contract research organization, medical centers, hospitals, pharmacies, and dispensaries. Through this supportive network, the Company aims to advance the proofof-concept clinical trial currently underway in the US. We anticipate expanding our network to hundreds of participating vendor partners.
Raphael Pharmaceutical intends to outsource the manufacturing and distribution of its cannabis-based medical indication formulations that achieve FDA phase 2 and EMA approvals.
Raphael Pharmaceutical anticipates that, upon regulatory approval, its cannabis-based medical indication formulations would be used by the public on a regular basis. Dosing recommendations would be indicated on the packaging akin to conventional, over-the-counter medicines.
For those cannabis-based medical indication formulations that need personal medical treatment for each patient, participating vendor partners will communicate directly with Raphaelappointed medical centers, which will instruct the patients and provide prescriptions for the illness treatments indicating the dosage, frequency and methods of use. The patients will be referred to the participating vendor partners to obtain Raphael’s medical products. The treatment progress will be followed up by Raphael’s medical teams and the data will be sent to Raphael’s headquarters and accumulated for future study.
After the trial period ends and results for the business model prototype have been analyzed, Raphael will develop further venues to increase manufacturing and distribution capacity on a larger scale. First in California, expanding to Colorado and Oklahoma, followed by the rest of the United States, and then to the rest of the world. Raphael Pharmaceutical anticipates that, upon FDA phase 2 approval, its revenues will be based on royalties paid to the Company for the use of its to-be patented, cannabis-based medical indication formulations. The Company’s products will be made by GMP-designated plants with the highest medical standards in California, the broader US, and throughout the world.
decoding medical cannabis and its benefits
We recognize that cannabis is the medicinal drug of the future. We are engaged in the development of cannabisbased medicine and treatments, as well as unique, patented cannabis strains, with the aim of achieving FDA Phase 1 and Phase 2 approval.
We have partnered with the Medical Cannabis Research Team at Rambam Health Care Campus on a long-term, exclusive, scientific project to develop cannabis-based medical indication formulations.
We are investing in the research and development of medicinal cannabis that is effective in treating rheumatoid arthritis and autoimmune disease/chronic lung inflammation, as well as in providing pain relief for oncology patients.
As pioneers in the industry, we plan to manufacture and distribute our medicines globally through the cooperation of industry leaders in the market.
The cannabis plant has a variety of strains and contains multiple compounds. To date, many such compounds have been identified, some of which are known to be involved in the beneficial effects of the plant and its derivative products. Up until recently, most of the medical community’s understanding of how these chemical compounds work therapeutically has come from anecdotal evidence.
Our goal is to decipher cannabinoids’ medicinal properties by performing scientific studies in state-of-the-art research facilities.
research and development
a roadmap to success
Raphael Pharmaceutical has partnered with the Medical Cannabis Research and Innovation Center (MCRIC), at Rambam Health Care Campus, Haifa, one of the leading centers for cannabis research in Israel.
Rheumatoid Arthritis
We are sponsoring immense scientific studies to define the potential of our cannabis strains to address rheumatology diseases, such as relieving arthritic inflammation of the joints and rheumatology-related chronic pain.
These studies are designed to reveal the mechanism of activities of our strains at the level of cell biology in mouse disease models and human patients. These molecular and biochemical studies are done in the MCRIC laboratories, which are highly regulated by the Israeli Ministry of Health, and the clinical study will be completed under FDA regulation.
Oncology
There is an urgent need for further knowledge in the case of palliative effects of cancer treatment including cachexia, fatigue, anemia, pain and depression.
Oncology-related studies will be held at MCRIC at Rambam Health Care Campus. The acquired data will be used to set up a platform for identifying, analyzing and matching the specific cannabis treatment to the specific cannabinoids’ receptors, which are expressed in the patient's cells.
Raphael Pharmaceuticals is investigating our proprietary strains as potential palliative treatment for young and adult patients under different protocols of cancer treatment. As part of our efforts to design a novel, cannabis-based treatment to relieve symptoms in young patients, we are collaborating with Schneider Children's Medical Center of Israel. Additionally, to study cancer related palliative effects in adult patients, we are also evaluating and investigating our proprietary strains at the Oncology and Hematology departments at Rambam Health Care Campus.
Autoimmune Disease / Chronic Lung Inflammation
Chronic lung inflammation is a prolonged inflammatory response in the lungs that can lead to tissue damage and impaired lung function. It is often associated with autoimmune diseases, where the immune system mistakenly attacks the body's own tissues. In autoimmune-related lung inflammation, immune cells infiltrate the lung tissue, releasing cytokines and other inflammatory mediators that cause persistent inflammation. Conditions such as rheumatoid arthritis, systemic lupus erythematosus, and sarcoidosis can involve chronic lung inflammation as a secondary complication. Together with the Medical Cannabis Research Institute at Rambam Health Care Campus, Raphael Pharmaceutical revealed in human and mouse model studies, that a specific strain (CBX) is effective in preventing immune cell communication, thus reducing cytokine storms and chronic lung inflammation. On the basis of these findings, Raphael Pharmaceutical aims to develop targeted medicines that disrupt the intercellular communication pathways involved in chronic inflammation and autoimmune diseases. Our findings were published in Frontiers in Immunology in May 2022.
Personalized Medicine
One of Raphael Pharmaceutical’s roadmaps to success is the need to identify the cannabinoid receptors in human biopsies. It is already known that cannabinoids interact differently with specific receptors in human cells. To obtain a deep understanding of the action mechanism of our cannabis strains, we have established a novel study which aims to identify the specific cannabinoids receptors in the cells of the treated patients.
The precision of our trajectory will enable our treatment to be more efficient and accurate, thus leading to personalize our prescriptions to each individual patient.
leadership
Scientific team
Prof. Joseph Press MD
Science Advisor
Former general director of Schneider Children’s Medical Center of Israel. Former Director of the Department of Pediatric Emergency Medicine, and Chair of the Pediatrics Division at Soroka University Medical Center.
Dr. Igal Louria-Hayon
Raphael Pharmaceutical CTO,
Chief Scientist, Director of the Scientific Advisory Board
Scientific director of the Medical Cannabis Research and Innovation Center at Rambam Health Care Campus and Head of the Leukemia & Immunotherapy Research Laboratory in the Clinical Research Institute at Rambam. In addition, Dr. Louria-Hayon served as Senior Research Fellow in the Technion's Cannabinoid Research Laboratory.
.jpg)
Dr. Shachar Eduardo
Frontline Director of Clinical Trials (Rambam),
Scientific Advisory Board Member
Director of the Clinical Immunology Unit at Rambam Health Care Campus.
Prof. Alexandra Balbir-Gurman
Frontline Director of Clinical Trials (Rambam), Scientific Advisory Board Member
Director of the B. Shine Rheumatology Unit at Rambam Health Care Campus, a member of the Executive Committee of the Israeli Society of Rheumatology, an active member of the Scleroderma Research Group (EUSTAR) and a member of the EULAR Target US initiative.
management team
Shlomi Pilo
CEO and BOD Chairman
Served four years in the Israeli army as an officer in an intelligence elite platoon. Served as VP Sales & Marketing of Alle Processing, which is the world's largest Glatt Kosher food manufacturer, from 1993 to 2011. During this time, helped the company grow its revenues from $23 million to over $100 million. Owner of food brokering company that represents seven food manufacturers in Europe and North America and serves giant club stores, such as Costco and BJ’s Wholesale Club.
Guy Ofir
General Council, CFO and BOD Member
Director of Raphael Pharmaceutical’s legal department and Board member. Lawyer and owner of "Guy Ofir Adv" law firm since 2000, practicing in civil and business law. In 2006, established and registered Easy Energy, Inc., a green energy company. Real estate developer in Romania since 2005.
